Skip to main content

Roche

F. Hoffmann-La Roche AG is a Swiss multinational healthcare enterprise that discovers, develops, and manufactures innovative pharmaceuticals and diagnostic instruments worldwide. The company conducts its operational activities through two primary business divisions: Pharmaceuticals and Diagnostics. Its commercial product portfolio includes market-leading biopharmaceutical therapeutics for oncology, immunology, ophthalmology, and neuroscience, alongside automated in vitro diagnostic systems and PCR testing kits. Principal revenue drivers consist of global commercial sales of proprietary prescription biopharmaceuticals, such as Ocrevus, Hemlibra, and Perjeta, complemented by diagnostic equipment and assay kit sales. Roche serves diverse healthcare end markets including hospital networks, clinical laboratories, pathology centers, medical specialists, and patients across more than one hundred countries. The enterprise holds a dominant global market position as the world's largest provider of oncology medicines and a premier provider of in vitro diagnostics. Headquartered in Basel, Switzerland, the company's non-voting equity securities are primary listed on the SIX Swiss Exchange under ticker symbol ROG and trade globally.

156 of the funds FundTelligence covers report a position in Roche.

Sector
Health Care
Country
Switzerland
Funds holding it
156
Exposure themes
Cancer, Diagnostics and screening, Prevention, Treatment, Women's Health

Funds holding Roche

Showing the 8 largest of 156 funds holding it.

Loading...